MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs

PARP1 is required for the maintenance of MLL-AF9 leukemias. PARP1 inhibitors enhance the therapeutic effect of cytotoxic drugs against MLL-AF9 leukemias.

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Maifrede, Silvia, Martinez, Esteban, Nieborowska-Skorska, Margaret, Di Marcantonio, Daniela, Hulse, Michael, Le, Bac Viet, Zhao, Huaqing, Piwocka, Katarzyna, Tempera, Italo, Sykes, Stephen M., Skorski, Tomasz
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2017
Pynciau:
Stimulus Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728460/
https://ncbi.nlm.nih.gov/pubmed/29296788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017006247
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg